Aimmune Therapeutics, Inc. (NASDAQ:AIMT) insider Daniel C. Md Adelman sold 9,933 shares of the business’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $40.00, for a total value of $397,320.00. Following the completion of the sale, the insider now directly owns 26,784 shares in the company, valued at approximately $1,071,360. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Aimmune Therapeutics, Inc. (AIMT) opened at $37.83 on Thursday. The stock has a market capitalization of $1,931.29, a price-to-earnings ratio of -16.10 and a beta of -0.66. Aimmune Therapeutics, Inc. has a 1-year low of $15.97 and a 1-year high of $40.65.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its earnings results on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.72) by $0.09. research analysts forecast that Aimmune Therapeutics, Inc. will post -2.51 EPS for the current year.

A number of analysts have recently commented on the company. Credit Suisse Group set a $45.00 price objective on Aimmune Therapeutics and gave the stock a “buy” rating in a research note on Thursday, January 11th. BidaskClub downgraded Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, January 4th. Zacks Investment Research downgraded Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, January 8th. ValuEngine downgraded Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Finally, Robert W. Baird assumed coverage on Aimmune Therapeutics in a research note on Wednesday, December 20th. They issued an “outperform” rating and a $64.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $55.43.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Point72 Asset Management L.P. grew its holdings in shares of Aimmune Therapeutics by 10.2% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,098,087 shares of the biotechnology company’s stock worth $27,222,000 after acquiring an additional 101,855 shares during the last quarter. GSA Capital Partners LLP acquired a new position in shares of Aimmune Therapeutics in the 2nd quarter worth $442,000. Goldman Sachs Group Inc. grew its holdings in shares of Aimmune Therapeutics by 139.9% in the 2nd quarter. Goldman Sachs Group Inc. now owns 227,377 shares of the biotechnology company’s stock worth $4,675,000 after acquiring an additional 132,603 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Aimmune Therapeutics by 16.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 131,353 shares of the biotechnology company’s stock worth $2,700,000 after acquiring an additional 19,016 shares during the last quarter. Finally, Citadel Advisors LLC acquired a new position in shares of Aimmune Therapeutics in the 2nd quarter worth $360,000. Institutional investors and hedge funds own 73.34% of the company’s stock.

WARNING: This piece was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.watchlistnews.com/aimmune-therapeutics-inc-aimt-insider-daniel-c-md-adelman-sells-9933-shares/1811751.html.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Insider Buying and Selling by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.